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Abstract 
The use of antipsychotics in dementia has been a concern. This study aimed to report 
the prevalence of antipsychotics in people with dementia and explore their use 
according to the living conditions (residential homes vs. community). Two groups of 
people with dementia were studied. Group 1 (n=38) was a convenience sample from the 
community and group 2 (n=38) was a randomised sample from residential homes. 
Socio-demographics, living condition and use of antipsychotics data were collected. 
Cognition and severity of dementia were assessed with the Mini-Mental State 
Examination. Of the total sample, 55.3% were prescribed with antipsychotics (1.2 ± 
0.4). The groups were similar at baseline for marital status, education, cognition and 
severity of dementia. However, institutionalised participants (71.1%) were higher 
prescribed with antipsychotics than participants from the community (28.9%). The 
institutionalisation seems to influence the use of antipsychotics in people with dementia. 
 
Introduction 
Antipsychotic medication is widely used for the management of behavioural and 
psychological symptoms of dementia such as, agitation, wandering, anxiety and 
aggressive behaviours (Nishtala et al., 2009; Giron et al., 2001; Hartikainen et al., 
2003). The evidence suggests that this medication increases the risk of dying, having a 
stroke and intensifies cognitive decline in older people with dementia with relatively 
modest benefits, i.e., the risk of its use is higher than its benefits (Schneider et al., 2006; 
Douglas and Smeeth, 2008). Therefore, there has been an international concern over the 
excessive and potential inappropriate use of antipsychotics in dementia (Oborne et al., 
2002; O’Brien, 2008; Alzheimer's Society, 2011). Non-pharmacological interventions 
have been proposed, for example, multisensory stimulation, reality orientation, motor 
stimulation or reminiscence therapy, (Rabins et al., 2007; Fossey et al., 2006) as 
potential interventions to reduce the need of antipsychotic medication. Practice 
guidelines have also recommended the use of psychological or environmental 
management options as a first line approach to deal with behavioural and psychological 
symptoms of dementia and antipsychotics interruption, if symptoms have been absent or 
minimal for three months (Howard et al., 2001). Nevertheless, high levels of 
antipsychotic medication in people with dementia continue to be administered (Nishtala 
et al., 2009).  
Most of the available evidence resulted from studies conducted in residential homes 
(Oborne et al., 2002; Alldred et al., 2007; Connelly et al., 2010) and research looking at 
medication prescription in different settings, e.g., residential homes vs. community, is 
lacking (Oborne et al., 2002; Alldred et al., 2007; Connelly et al., 2010). This 
information is essential to guide health professionals’ practice and to estimate the 
workload implications as well as the resources needed to reduce inappropriate 
prescription (Shah et al., 2011). Therefore, this study aimed to report the prevalence of 
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antipsychotics in people with dementia and explore their use according to the living 
conditions, i.e., residential homes vs. community. 
 
Methods 
A cross-sectional study of people with medical diagnosis of dementia according to 
the DSM-IV criteria was performed in the central region of Portugal. Ethical approval 
was previously obtained by the Ethics Committee of the Research Unit of Health 
Sciences at the Health School of Nursing in Coimbra, Portugal. Written informed 
consent was obtained from the legal representatives of the participants.  
Two groups of people with dementia were studied. Group 1 (n=38) was a 
convenience sample recruited from the community (day centres and home support 
services). Group 2 (n=38) was a randomised sample selected from a larger sample of 
329 people with dementia in residential homes. 
Socio-demographics, living condition and use of antipsychotics data were collected 
through a structured questionnaire based on ICF-checklist (World Health Organization, 
2001). Cognition and severity of dementia was assessed with the Mini-Mental State 
Examination (MMSE). According to European studies (Fernandez, Gobartt, Balana, & 
Group, 2010; Miranda-Castillo et al., 2010), a MMSE score between 27-21 was 
considered mild dementia, 20-11 moderate dementia and 10-0 severe dementia. 
Statistical analyses were performed using the PASW Statistics 18.0 for Windows. 
Descriptive statistics were applied to characterise the sample. The Mann-Whitney non-
parametric test was applied to assess the differences of socio-demographics, cognition, 
severity of dementia and antipsychotics prescription in the two groups, as the parametric 
requirements were not verified. The level of significance considered was 0.05. 
 
Results 
Table 1 summarises the sample characteristics. Group 1 mean age was 77.8±6.3 
years old. Half of the participants were female (n=19), most were married (n=22) and 
had 1 to 4 years of education (n=22). Group 2 mean age was 83.7±6.3 years old. Most 
were female (n=31), widows (n=24) and had 1 to 4 years of education (n=17).  
Of the total sample, 55.3% (n=42) were prescribed with one or more antipsychotics 
(1.2 ± 0.4). No statistical significant differences were found between the groups for 
marital status (ρ=0.12), level of education (ρ=0.16), cognition (ρ=0.09) and severity of 
dementia (ρ=0.05). Institutionalised people with dementia (n=27; 71.1%) were 
significantly higher prescribed with antipsychotics than participants living in the 
community (n=11; 28.9%). Therefore, the living condition (i.e., residential homes or 
community) were found to be significantly associated with the use of antipsychotics 
(ρ=0.001). 
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Table 1: Sample characterisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
Antipsychotics are highly prescribed in people with dementia and their higher use 
seems to be related with the institutionalisation. This result is in line with previous 
studies that reported a high amount of antipsychotics intake in people with dementia in 
residential homes (Nishtala et al., 2009; Alzheimer's Society, 2011; Shah et al., 2011; 
Feng et al., 2009). 
Antipsychotics prescription is a serious health problem as: i) they are used as first 
line approach, without exploring other non-pharmacological strategies such as, trying to 
change the environment, interactions or the person life conditions (Musicco et al., 
2011); ii) they are associated with a high number of side effects, which in most cases 
are not previously explored for each person (Schneider et al., 2006; Douglas and 
Smeeth, 2008); iii) people with dementia are repeatedly prescribed without regular 
medical revision (Shah et al., 2011; National Institute for Health and Clinical 
Excellence and National Collaborating Centre for Mental Health, 2006; Banerjee, 
2009). Therefore, this matter requires awareness and appropriate measures.  
Although a lower prescription of antipsychotics was found in the community, this 
study is limited by the small sample size. Further research should be conducted in 
community settings, with larger and randomised samples to improve knowledge, as 
prescription in the community is less well explored and documented (Shah et al., 2011). 
Research is also needed on non-pharmacological interventions, which have been 
Sample characterisation Group 1 Group 2 
n % n % 
Gender 
Female 
Male 
 
19 
19 
 
50 
50 
 
21 
17 
 
55.3 
44.7 
Marital status 
Single 
Married/Living with a partner 
Divorced/Separated 
widowed 
 
3 
22 
1 
12 
 
7.9 
57.9 
2.6 
31.6 
 
7 
6 
1 
24 
 
18.4 
15.8 
2.6 
63.2 
Level of education (years) 
Illiterate 
1-4 
5-9 
+10 
Missing 
 
9 
22 
3 
2 
2 
 
23.7 
57.9 
7.9 
5.3 
5.3 
 
14 
17 
4 
1 
4 
 
36.8 
44.7 
10.5 
2.6 
10.5 
Severity of dementia 
Mild 
Moderate 
Severe 
 
5 
20 
13 
 
13.2 
5.3 
34.2 
 
4 
10 
22 
 
10.5 
26.3 
57.9 
Cognition (Mean± SD) 12.7±7.2 9.4±9.4 
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described as promising approaches to reduce the need of antipsychotics in people with 
dementia (Rabins et al., 2007; Fossey et al., 2006) however, the evidence on their 
implementation remains scarce. 
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